These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof. Slide 2 Moderna COVID-19 Vaccine: Authorized Use & Important Safety Information Authorized Use in the United States: Moderna COVID-19 Vaccine is authorized for use under an ...
To date, Moderna has demonstrated positive Phase 1 data readouts for seven prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV/PIV3, CMV and Zika). Moderna’s CMV vaccine is currently in a Phase 2 dose-confirmation study. Moderna’s investigational Zika vaccine (mRNA-1893), c...
Moderna is well-prepared for the launch of its second respiratory vaccine, which will build upon the success of its commercial efforts in the fall COVID-19 market. The Company is encouraged by early indications of widespread consumer awareness and established demand ...
Moderna Shares Fall As Vaccine Maker Cuts R&D Spending Plans Sep. 12, 2024 at 7:28 a.m. ET Other News Press Releases Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season Oct. 18, 2024 at 9:23 a.m. ET on Benzinga.com VOO ETF Update, 10/18/2024...
Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine
Moderna, Inc. today announced that it has submitted a request for emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age to the U.S. Food a...
Zika vaccine (mRNA-1893 with BARDA) Vaccines against highly prevalent viral infections Epstein-Barr virus (EBV) vaccine (mRNA-1189) To date, Moderna has demonstrated positive Phase 1 data readouts for seven prophylactic vaccines (H10N8, H7N9, RSV, chiku...
(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that Merck has exercised its option to jointly ...
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the development by Moderna and Merck of a personalized cance...
GMT ratios for mRNA-1083 relative to Fluzone HD in adults 65-79 were also >1.0, for all four influenza vaccine strains. The GMT ratios of mRNA-1083 relative to Spikevax bivalent were > 0.9 in adults 50 to 64 years of...